Continuation of R&D Activities
First written in FY2016-Q3. 22 of 30 entries say "Restated". Latest entry: FY2026-H1.
96 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The group-wide amount of research and development activities during the interim consolidated accounting period was ¥3,188 million. There were no material changes in the status of the group’s research and development activities during the interim consolidated accounting period.」
The company disclosed research and development expenses of ¥3,188 million and stated that there were no material changes in the status of its research and development activities. - FY2025-H1RestatedAnnual report
「The group-wide amount of research and development activities during the interim consolidated accounting period was ¥2,250 million. There were no material changes in the status of the group’s research and development activities during the interim consolidated accounting period.」
The company disclosed research and development expenses of ¥2,250 million and stated that there were no material changes in the status of its research and development activities. - FY2024AdvancedAnnual report
「Research and development expenses for the fiscal year totaled ¥4,507 million. For the ventricular assist device developed by Sun Medical Technology Research Institute Co., Ltd., the design of a smaller next-generation artificial heart with enhanced measures against complications was completed, and the company began collecting data for regulatory approval.」
Research and development expenses totaled ¥4,507 million. Specific development progress was described, including completion of the next-generation artificial heart design, commencement of data collection for regulatory approval, and overseas approval of new microcatheters and guidewires. - FY2024-Q2RestatedAnnual report
「The group-wide amount of research and development activities during the nine-month period ended the second quarter was ¥2,099 million. There were no material changes in the status of the group’s research and development activities during the nine-month period ended the second quarter.」
The company disclosed research and development expenses of ¥2,099 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q1RestatedAnnual report
「The group-wide amount of research and development activities during the three-month period ended the first quarter was ¥1,043 million. There were no material changes in the status of the group’s research and development activities during the three-month period ended the first quarter.」
The company disclosed research and development expenses of ¥1,043 million and stated that there were no material changes in the status of its research and development activities. - FY2023AdvancedAnnual report
「For the ventricular assist device developed by Sun Medical Technology Research Institute Co., Ltd., implantation was performed at 22 U.S. clinical-trial sites in 28 cases, and full-scale clinical trials are progressing.」
For the ventricular assist device, implantation was performed in 28 cases at 22 sites in the United States, and full-scale clinical trials are progressing. Total research and development expenses amounted to ¥4,421 million. - FY2023-Q3RestatedAnnual report
「The group-wide amount of research and development activities during the nine-month period ended the third quarter was ¥3,041 million. There were no material changes in the status of the group’s research and development activities during the nine-month period ended the third quarter.」
The company disclosed research and development expenses of ¥3,041 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「The group-wide amount of research and development activities during the nine-month period ended the second quarter was ¥1,952 million. There were no material changes in the status of the group’s research and development activities during the nine-month period ended the second quarter.」
The company disclosed research and development expenses of ¥1,952 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「The group-wide amount of research and development activities during the three-month period ended the first quarter was ¥1,205 million. There were no material changes in the status of the group’s research and development activities during the three-month period ended the first quarter.」
The company disclosed research and development expenses of ¥1,205 million and stated that there were no material changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「Research and development expenses for the fiscal year totaled ¥3,975 million. For the ventricular assist device developed by Sun Medical Technology Research Institute Co., Ltd., 15 cases for U.S. clinical-trial safety confirmation were completed with favorable results, and the project moved to full-scale clinical trials.」
Research and development expenses totaled ¥3,975 million. For the ventricular assist device, 15 cases for U.S. clinical-trial safety confirmation were completed, and the project moved to full-scale clinical trials. Specific progress in the research and development activities was described. - FY2022-Q3RestatedAnnual report
「The group-wide amount of research and development activities during the nine-month period ended the third quarter was ¥2,756 million. There were no material changes in the status of the group’s research and development activities during the nine-month period ended the third quarter.」
The company continued its research and development activities and disclosed research and development expenses of ¥2,756 million. It stated that there were no material changes in the status of its activities. - FY2022-Q2RestatedAnnual report
「The group-wide amount of research and development activities during the nine-month period ended the second quarter was ¥1,866 million. There were no material changes in the status of the group’s research and development activities during the nine-month period ended the second quarter.」
The company continued its research and development activities and disclosed research and development expenses of ¥1,866 million for the nine-month period ended the second quarter. It stated that there were no material changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the three-month cumulative period of the current first quarter was ¥941 million. There were no material changes in the status of the Group's research and development activities during the three-month cumulative period of the current first quarter.」
It disclosed first-quarter research and development expenses of ¥941 million and stated that there had been no material changes in the status of research and development activities. - FY2021-Q3RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥2,696 million. There were no material changes in the status of the Group's research and development activities during the nine-month cumulative period of the current third quarter.」
It disclosed research and development expenses of ¥2,696 million and stated that there had been no material changes in the status of research and development activities. - FY2021-Q2RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the six-month cumulative period of the current second quarter was ¥1,779 million. There were no material changes in the status of the Group's research and development activities during the six-month cumulative period of the current second quarter.」
It disclosed research and development expenses of ¥1,779 million and stated that there had been no material changes in the status of research and development activities. - FY2020AdvancedAnnual report
「With respect to the ventricular assist devices of 株式会社サンメディカル技術研究所, development of a further downsized external controller has been completed, following the minimally invasive small pump, the ventricular cannula without protrusions, and the polyester outflow graft designed for ease of use by surgeons, all of which were introduced from the previous year. A regulatory application is currently pending.」
In addition to continuing its research and development activities, it completed development of a downsized external controller for a ventricular assist device and advanced to the regulatory application stage. Total research and development expenses were disclosed as ¥3,442 million. - FY2020-Q3RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥2,555 million. There were no material changes in the status of the Group's research and development activities during the nine-month cumulative period of the current third quarter.」
It stated that there had been no material changes in the status of research and development activities and disclosed research and development expenses of ¥2,555 million for the nine-month cumulative period of the current third quarter. - FY2020-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the three-month cumulative period of the current first quarter was ¥867 million. There were no material changes in the status of the Group's research and development activities during the three-month cumulative period of the current first quarter.」
It disclosed first-quarter research and development expenses of ¥867 million and stated that there had been no material changes in the status of research and development activities. - FY2019AdvancedAnnual report
「In addition, total research and development expenses for the current consolidated fiscal year were ¥3,780 million. As a welfare and nursing-care product for an aging society, the company newly developed a bathing assistance device to reduce the burden of caregiving and introduced it to the advance market.」
It disclosed research and development expenses and developed and introduced a bathing assistance device to the advance market. For the ventricular assist device, it introduced an outflow graft and described the downsizing of the external controller and plans to file a regulatory application in the following fiscal year. - FY2019-Q3RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥3,002 million. There were no material changes in the status of the Group's research and development activities during the nine-month cumulative period of the current third quarter.」
It disclosed research and development expenses of ¥3,002 million for the nine-month cumulative period of the third quarter and stated that there had been no material changes in the status of research and development activities. - FY2019-Q2RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the six-month cumulative period of the current second quarter was ¥2,003 million. There were no material changes in the status of the Group's research and development activities during the six-month cumulative period of the current second quarter.」
It disclosed research and development expenses of ¥2,003 million for the six-month cumulative period of the second quarter and stated that there had been no material changes in the status of research and development activities. - FY2019-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the three-month cumulative period of the current first quarter was ¥1,044 million. There were no material changes in the status of the Group's research and development activities during the three-month cumulative period of the current first quarter.」
It stated that there had been no material changes in the status of research and development activities and disclosed quarterly research and development expenses of ¥1,044 million. - FY2018-Q3RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥3,293 million. There were no material changes in the status of the Group's research and development activities during the nine-month cumulative period of the current third quarter.」
It disclosed research and development expenses of ¥3,293 million for the nine-month cumulative period of the third quarter and stated that there had been no material changes in the status of research and development activities. - FY2018-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the three-month cumulative period of the current first quarter was ¥1,171 million. There were no material changes in the status of the Group's research and development activities during the three-month cumulative period of the current first quarter.」
It disclosed research and development expenses of ¥1,171 million for the three-month cumulative period of the first quarter and stated that there had been no material changes in the status of research and development activities. - FY2017AdvancedAnnual report
「In addition, total research and development expenses for the current consolidated fiscal year were ¥3,923 million. Regarding the application status of a next-generation small, high-flow pump that can be implanted without difficulty even in smaller patients, approval of applications in Japan and the United States is expected shortly, while the review process has begun in Europe and the product is nearing launch.」
Research and development expenses were ¥3,923 million, with specific progress reported for the next-generation small pump: applications in Japan and the United States were nearing approval, while the product was under review and nearing launch in Europe. - FY2017-Q3RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥3,022 million. There were no material changes in the status of the Group's research and development activities during the nine-month cumulative period of the current third quarter.」
It disclosed research and development expenses of ¥3,022 million for the nine-month cumulative period of the third quarter and stated that there had been no material changes in the status of research and development activities. - FY2017-Q2RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the six-month cumulative period of the current second quarter was ¥1,950 million. There were no material changes in the status of the Group's research and development activities during the six-month cumulative period of the current second quarter.」
It disclosed research and development expenses of ¥1,950 million for the six-month cumulative period of the second quarter and stated that there had been no material changes in the status of research and development activities. - FY2017-Q1RestatedAnnual report
「The amount of research and development activities for the Group as a whole during the three-month cumulative period of the current first quarter was ¥819 million. There were no material changes in the status of the Group's research and development activities during the three-month cumulative period of the current first quarter.」
It disclosed quarterly research and development expenses of ¥819 million and stated that there had been no material changes in the status of research and development activities. - FY2016AdvancedAnnual report
「Total research and development expenses for the current consolidated fiscal year were ¥3,847 million.」
It disclosed total research and development expenses of ¥3,847 million. It also described specific progress in development and commercialization, including the development of new materials, technologies and products, the start of manufacturing and sales of artificial blood vessels, obtaining the European CE Marking for EVAHEART, and preparations for filing an application for a next-generation small blood pump. - FY2016-Q3First statedAnnual report
「The amount of research and development activities for the Group as a whole during the nine-month cumulative period of the current third quarter was ¥2,929 million.」
It disclosed expenditure on research and development activities and stated that there had been no material changes in the status of those activities.